WANG Kun. Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment to Improve the Overall Survival of Patients with Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002
|
Citation:
|
WANG Kun. Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment to Improve the Overall Survival of Patients with Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002
|
WANG Kun. Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment to Improve the Overall Survival of Patients with Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002
|
Citation:
|
WANG Kun. Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment to Improve the Overall Survival of Patients with Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002
|
DownLoad: